Please login to the form below

lebrikizumab

This page shows the latest lebrikizumab news and features for those working in and with pharma, biotech and healthcare.

Dermira craters as acne drug fails late-stage test

Also in its pipeline is an injectable drug for atopic dermatitis - I L-13 inhibitor lebrikizumab - which was developed by Roche and licensed to Dermira in a deal valued at up ... That programme is in mid-stage clinical testing. Even if it successfully

Latest news

Setback for AZ as tralokinumab flunks asthma trial

The failure of tralokinumab hasn’t come out of the blue, as another trial (STRATOS 1) also failed to hit the mark, and other IL-13 inhibitors - including Roche’s lebrikizumab
Roche out-licenses lebrikizumab rights to Dermira

Roche out-licenses lebrikizumab rights to Dermira. Swiss drug maker stands to receive $80m upfront for the drug. ... Roche has opted to out-license the bulk of the rights to its IL-13 inhibitor lebrikizumab to dermatology company Dermira in a deal valued
AZ trial adds to pessimism about anti-IL-13 asthma drugs

It looks increasingly like a lost cause as AZ already reported disappointing phase IIb data with tralokinumab, and last year Roche reported disappointing results with its anti-IL-13 candidate lebrikizumab,
Teva gets EU nod for severe asthma drug Cinqaero

13 inhibitor lebrikizumab.
Roche shares slip as profits miss expectations

Aside with atezolizumab, Roche is also looking ahead to possible launches for multiple sclerosis candidate ocrelizumab - also due for filing shortly - as well as asthma drug lebrikizumab.

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

Pharma deals during August 2014

This brings a much needed boost to its respiratory portfolio, which currently consists of Pulmozyme (cystic fibrosis) and Xolair (severe asthma) and products in clinical development, eg lebrikizumab (severe asthma).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Senior Medical Writer (Remote Working): Competitive Salary Offered

Director – Head of Public Affairs: Neg

Experienced Editor, London, Medical Communications: Competitive package

Account Director – Global Healthcare PR: Salary TBC

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Director Healthcare PR Communications: Salary TBC

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Scientific Director: Highly Competitive Salary &Benefits

Scientific Team Lead: Competitive Salary

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Senior Account Executive – Medical Communications: Salary TBC

Associate Medical Director: Highly Competitive

Healthcare PR Director: £100, 000 – £120, 000 benefits

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Associate Medical Director: Salary TBC

Account Director - Digital: Great salary and benefits

Account Manager, Healthcare Advertising: Salary TBC

Account Director: Negotiable

Project / Account Manager (Medical Education): Salary TBC

Editorial Director – Medical Education: Neg

Subscribe to our email news alerts

PMHub

Add my company

3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe’s leading hub for life sciences innovation...
Tackling a formidable foe: Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...